• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO Mercer Patrick was granted 33,370 shares, increasing direct ownership by 9% to 420,100 units (SEC Form 4)

    6/17/25 9:52:09 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mercer Patrick

    (Last) (First) (Middle)
    1212 TERRA BELLA AVENUE

    (Street)
    MOUNTAIN VIEW CA 94043

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IRIDEX CORP [ IRIX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    06/17/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/13/2025 A 33,370(1) A $2 420,100 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Stock (right to buy)(2) $1.4 06/13/2025 A 111,240 (3) 06/13/2032 Common Stock 111,240 $0 111,240 D
    Explanation of Responses:
    1. Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest as to one-third of the shares on June 13, 2026 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
    2. This option granted pursuant to IRIDEX Corporation's 2008 Amended and Restated Equity Incentive Plan and is exempt pursuant to Rule 16b-3.
    3. The shares are subject to vesting according to the following schedule: 1/3 of the Shares subject to the Option will vest each one-year anniversary of the date of grant.
    /s/ Nilo De Castro, Attorney-in-fact for Patrick Mercer 06/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moore William M bought $19,372 worth of shares (20,000 units at $0.97), increasing direct ownership by 12% to 188,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/16/25 1:44:46 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Mercer Patrick bought $240 worth of shares (250 units at $0.96), increasing direct ownership by 0.06% to 386,730 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 2:43:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Moore William M bought $29,121 worth of shares (30,000 units at $0.97), increasing direct ownership by 22% to 168,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 1:28:06 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      5/12/21 11:32:01 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on IRIDEX with a new price target

      Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/9/21 8:09:06 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/3/21 12:29:03 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care